id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S9790 R35053 |
Vajda (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.09 [0.11;40.14] C excluded (control group) |
0/5 20/406 | 20 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9791 R35054 |
Vajda (Ethosuximide) (Controls unexposed, sick), 2019 | Fetal malformations | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 3.44 [0.16;72.20] C | 0/5 5/176 | 5 | 5 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9789 R35051 |
Tomson (Ethosuximide), 2018 | Malformed Offspring | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.42 [0.08;24.39] C | 0/12 74/2,514 | 74 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9780 R35024 |
Källén (Ethosuximide) (Controls exposed to Lamotrigine, sick) (Indications NOS), 2013 | Relatively severe malformations | early pregnancy | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
2.57 [0.32;20.45] C excluded (control group) |
1/12 37/1,084 | 38 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9781 R35026 |
Källén (Ethsuximide) (Controls unexposed, NOS) (Indications NOS), 2013 | Relatively severe malformations | early pregnancy | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: No | 2.80 [0.36;21.71] C | 1/12 49,499/1,575,847 | 49,500 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9782 R35034 |
Bànhidy (Ethosuximide), 2011 | Total congenital abnormalities | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 4.13 [0.18;96.94] C | 2/2 12/22 | 14 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9786 R35039 |
Morrow (Ethosuximide) (Controls exposed to Lamotrigine, sick), 2006 | Major congenital malformation | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
1.26 [0.07;22.17] C excluded (control group) |
0/12 21/647 | 21 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9787 R35047 |
Morrow (Ethosuximide) (Controls unexposed, sick), 2006 | Major congenital malformation | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.12 [0.06;20.58] C | 0/12 8/227 | 8 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9783 R35035 |
Kaaja (Ethosuximide), 2003 | Major malformation | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 31.53 [1.02;978.23] C | 0/2 2/239 | 2 | 2 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9779 R35008 |
Dean (Ethosuximide), 2002 | Major congenital malformations | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 2.03 [0.08;51.22] C | 0/4 2/38 | 2 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9788 R35049 |
Samrén (Ethosuximide), 1999 | Major congenial abnormalities | at least 1st trimester | retrospective cohort | unexposed, disease free | Adjustment: No Matched | 3.93 [0.22;69.67] C | 0/9 29/2,000 | 29 | 9 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 8 studies | 3.05 [1.12;8.33] | 49,634 | 58 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Ethosuximide) (Controls unexposed, sick; 2: Ethosuximide; 3: Ethsuximide) (Controls unexposed, NOS) (Indications NOS; 4: Ethosuximide; 5: Ethosuximide) (Controls unexposed, sick; 6: Ethosuximide; 7: Ethosuximide; 8: Ethosuximide;
Asymetry test p-value = 0.4325 (by Egger's regression)
slope=-0.5412 (1.9956); intercept=1.1576 (1.3763); t=0.8411; p=0.4325
excluded 9786, 9780, 9790